Fuda Cancer Hospital
Fuda Cancer Hospital
Chiny, Kanton
Metastases in the liver treatment cost in China typically runs from $6,200 to $10,500 for chemoembolization of the liver. Surgical options like liver resection range from $18,500 to $38,500. Total expenses depend on the cancer stage, chosen technology, and hospital tier. Patients often save 40-60% compared to the US. Top cities for these advanced oncological procedures include Guangzhou and Beijing.
Typical Metastases In The Liver Treatment Costs In China
Bookimed Expert Insight: Patients with advanced or multi-focal metastases should prioritize clinics offering specialized minimally invasive technologies. Fuda Cancer Hospital in Guangzhou is a leading choice for these complex cases. They utilize JCI-accredited protocols for NanoKnife and cryosurgery to treat tumors in difficult locations. This approach is ideal for patients who are not candidates for traditional open surgery. The facility has successfully treated over 30,000 international patients using these targeted vascular interventional therapies.
| Chiny | Turcja | Austria | |
| Resekcja wątroby | od $18,500 | od $11,700 | od $35,000 |
| Resekcja w przypadku raka wątroby | od $21,500 | od $10,800 | od $40,000 |
| Chemoembolizacja wątroby | od $6,200 | od $7,500 | od $16,000 |
| Ablacja radiofrekwencyjna wątroby (RFA wątroby) | od $5,500 | od $3,500 | od $12,000 |
| Chemioterapia przy raku wątroby | od $3,500 | od $1,800 | - |
Państwo nie płacą za usługi Bookimed. Ceny leczenia przerzutów do wątroby odpowiadają cennikowi kliniki. Płatność dokonywana jest bezpośrednio w klinice po przyjeździe. Dostępna jest płatność w ratach.
Bookimed dba o Państwa bezpieczeństwo. Współpracujemy tylko z klinikami spełniającymi wysokie międzynarodowe standardy w leczeniu przerzutów do wątroby. Posiadają one wymagane licencje do obsługi pacjentów międzynarodowych na całym świecie.
Bookimed oferuje bezpłatną pomoc i wsparcie. Osobisty koordynator medyczny pozostaje w kontakcie przed, w trakcie i po podróży. Nie będą Państwo sami w innym kraju podczas leczenia przerzutów do wątroby.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Chinese oncology centers provide advanced Western treatments for liver metastases, focusing on minimally invasive ablation, catheter-directed therapies, and surgical resection. Accredited facilities like Fuda Cancer Hospital utilize JCI-standard protocols. These include NanoKnife and cryosurgery to target tumors while preserving healthy liver tissue.
Bookimed Expert Insight: Data from Fuda Cancer Hospital reveals a specialized focus on late-stage cases often deemed inoperable elsewhere. While many centers prioritize standard resection, Fuda utilizes a high volume of non-thermal NanoKnife procedures. This approach is specifically effective for metastases located near major blood vessels where heat-based ablation or surgery risks internal damage. This specialization has attracted patients from over 100 countries seeking alternatives for complex tumor locations.
Patient Consensus: Patients note that leading centers often propose aggressive multidisciplinary sequencing, moving quickly from systemic therapy to local interventions. Many emphasize the importance of bringing original biopsy reports and genomic results to avoid repeat testing delays.
China offers advanced non-invasive radiation options like Proton Beam Therapy through a rapidly expanding network of specialized oncology centers. Facilities in Shanghai and Guangzhou utilize high-precision particle therapy to treat complex liver metastases. These institutions maintain international standards with Joint Commission International accreditations and advanced delivery systems.
Bookimed Expert Insight: While Proton Beam Therapy is a major draw, high-volume centers like Fuda Cancer Hospital often prioritize a combination of NanoKnife and vascular interventional therapy for liver metastases. Data shows these minimally invasive techniques are frequently selected over radiation for late-stage cases. Patients should verify if a facility's 400-bed capacity includes dedicated space for international oncology recovery.
Patient Consensus: Patients note that while newer technology is attractive, doctors often recommend Stereotactic Body Radiation Therapy (SBRT) for liver lesions. They emphasize bringing complete pathology reports to ensure the tumor location actually qualifies for proton treatment.
China integrates Traditional Chinese Medicine (TCM) for liver metastases as a supportive therapy alongside Western protocols. Chinese oncology programs follow national guidelines to combine TCM with chemotherapy, immunotherapy, and interventional procedures. These integrative methods aim to optimize tolerance, support liver function, and manage treatment side effects.
Bookimed Expert Insight: While many Chinese centers provide integrative care, hospitals with JCI accreditation like Fuda Cancer Hospital emphasize specialized technologies. They utilize cryosurgery and NanoKnife for liver lesions alongside supportive interventional therapies. Leading oncologists in China, such as Professor Liu Shi Xin at Xiamen Humanity Hospital, participate in both the Chinese Medical Association and the Chinese Anti-Cancer Association. This ensures that TCM integration remains strictly under the supervision of qualified Western-trained medical experts.
Patient Consensus: Patients note that TCM helps them feel less destroyed by improving appetite and energy levels during chemo. They emphasize that measurable results come from Western medicine, while herbs serve as a practical way to manage day-to-day comfort.